<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00496457</url>
  </required_header>
  <id_info>
    <org_study_id>WN29860</org_study_id>
    <secondary_id>EudraCT Number: 2006-004545-42</secondary_id>
    <secondary_id>TRO19622 CLEQ 1104-1</secondary_id>
    <nct_id>NCT00496457</nct_id>
  </id_info>
  <brief_title>Efficacy Study With 500 mg QD of TRO19622 vs Placebo in Patients With Painful Peripheral Diabetic Neuropathy</brief_title>
  <official_title>A Double-Blind, Randomized, Multicenter Study With 500 mg QD of TRO19622 Versus Placebo in Patients With Painful Peripheral Diabetic Neuropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ergomed GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy and safety of TRO19622 administered PO&#xD;
      daily for 6 weeks compared to placebo administered PO daily in patients with painful&#xD;
      peripheral diabetic neuropathy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diabetic peripheral neuropathic pain (DPNP) affects approximately 11% of patients with&#xD;
      diabetic peripheral neuropathy (DPN). Diabetic neuropathy as the underlying disease is the&#xD;
      most common long-term complication of diabetes mellitus estimated to be experienced by a&#xD;
      majority of patients at least in a mild manner.&#xD;
&#xD;
      Many patients with (DPNP) do not respond adequately to any individual treatment option. None&#xD;
      of the various treatments used can be considered a cure. As a result, although a variety of&#xD;
      drugs are available for the treatment of diabetic neuropathic pain, there is a strong need to&#xD;
      develop new drugs with greater efficacy and/or fewer adverse effects.&#xD;
&#xD;
      The primary objective of the study is to compare the effect of TRO19622 versus placebo on the&#xD;
      24h neuropathic pain scores during the last 7 days of the 6-week treatment period.&#xD;
&#xD;
      Secondary objectives are to compare the efficacy on neuropathic pain, impact on emotional&#xD;
      functioning, safety profile, pain time course, and response rate of TRO19622 versus placebo.&#xD;
      Additionally, the pharmacokinetics of TRO19622 will be assessed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of TRO19622 versus Placebo on the mean 24h neuropathic pain score on the Likert numerical rating scale.</measure>
    <time_frame>During the last 7 days of the 6-week treatment period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>24h Pain time course</measure>
    <time_frame>Duration of study (within 11weeks after screening)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis for treatment effects: SF-MPQ, SF-BPI, SF36, POMS, Global Impression of Change (Patient / Investigator)</measure>
    <time_frame>Within 6 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>During the course of the study.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">159</enrollment>
  <condition>Diabetic Neuropathy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TRO19622</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Experimental</intervention_name>
    <description>Capsules of TRO19622 (125 mg)- Once a day before noon meal during 6 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo comparator</intervention_name>
    <description>4 Capsules of PBO per day before noon meal</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Be a male &gt;18 years or a post-menopausal female (&gt;60 years of age and at least 1 year&#xD;
             of amenorrhea).&#xD;
&#xD;
          -  Have painful diabetic neuropathy of &gt;6 months duration and are either pain treatment&#xD;
             naive or have important side effects or inadequate relief from their current pain&#xD;
             medication.&#xD;
&#xD;
          -  Be on current pain medication (prescribed analgesics), stable for at least 3 months&#xD;
             before study entry (± 25% dosage of basic pain medication, top-up rescue medication&#xD;
             allowed), or pain treatment naive.&#xD;
&#xD;
          -  Have stable diabetes, defined as HbA1c &lt;10%, no changes in medication in the previous&#xD;
             3 months, and no new symptoms associated with diabetes in the previous 3 months.&#xD;
&#xD;
          -  Have scored &gt;2 points on the Michigan Neuropathy Screening Instrument (MNSI), part&#xD;
             B-physical assessment by health professional.&#xD;
&#xD;
          -  Have an ECG without any clinically significant abnormality.&#xD;
&#xD;
        The following inclusion criteria should be ascertained at the baseline visit:&#xD;
&#xD;
          -  Have measurable pain perception (previous 24h) on the Likert numerical rating scale&#xD;
             with a mean≥4.0 points calculated from at least 4 daily measurements over the 7 days&#xD;
             immediately prior to the Baseline Visit.&#xD;
&#xD;
          -  Have stopped current pain medication at least 14 days prior to the Baseline Visit&#xD;
             (except rescue medication).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Be pregnant female, lactating female, or female of child bearing potential (≤60 years&#xD;
             of age).&#xD;
&#xD;
          -  Have a documented neuropathy of any cause other than those mentioned in the inclusion&#xD;
             criteria which might interfere with the assessment of the severity of pain (eg,&#xD;
             including, but not limited to, alcoholic, uremic, B12, TSH, chemotherapy, HIV, post&#xD;
             surgical, or post-traumatic neuropathy).&#xD;
&#xD;
          -  Have other neurological diseases that may produce weakness, sensory loss, or autonomic&#xD;
             symptoms, or laboratory test abnormality.&#xD;
&#xD;
          -  Have been on pain treatment with strong opioids, more than 4 different drug regimens&#xD;
             in the previous year, or a current combination of more than 2 drugs.&#xD;
&#xD;
          -  Have a current medication of lipid lowering agents other than statins.&#xD;
&#xD;
          -  Have a body mass index (BMI) &gt;40 kg/m2 (obesity grade III).&#xD;
&#xD;
          -  Had any surgery within the previous 2 months.&#xD;
&#xD;
          -  Have concurrent serious neurological disease (eg, dementia, multiple sclerosis, or any&#xD;
             other disease that would impact the ability of the patient to provide consent for&#xD;
             study participation).&#xD;
&#xD;
          -  Have a recent history (within the previous 6 months) or current evidence of alcohol or&#xD;
             drug abuse.&#xD;
&#xD;
          -  Have concurrent unstable disease involving any system (eg, advanced carcinoma,&#xD;
             myocardial infarction, clinical or ECG signs of myocardial ischemia, cardiac&#xD;
             insufficiency i.e.≥ NYHA functional classification class 2, anginal symptoms, current&#xD;
             symptoms of CAD, renal impairment, or any other condition that in the opinion of the&#xD;
             Investigator would make the patient unsuitable for study participation).&#xD;
&#xD;
          -  Participated in any other investigational drug or therapy study within the previous 3&#xD;
             months.&#xD;
&#xD;
          -  Changed or interrupted current well-tolerated medication during the previous 3 months.&#xD;
&#xD;
          -  Lack of ability or willingness to give informed consent.&#xD;
&#xD;
          -  Be possibly dependent on the Investigator or the Sponsor (eg, including, but not&#xD;
             limited to, affiliated employee).&#xD;
&#xD;
          -  Have hemostasis disorders or a current treatment of anticoagulants.&#xD;
&#xD;
          -  Have non-adequate renal and/or hepatic function as follows:&#xD;
&#xD;
               -  Renal - Blood creatinine &gt;1.5X upper limit of normal (ULN)&#xD;
&#xD;
               -  Hepatic - Liver enzymes (ALT and AST) &gt;2 X ULN&#xD;
&#xD;
          -  Have a known history of or current cardiac dysrhythmias and / or a known history of or&#xD;
             current cardiovascular disease including myocardial infarction except patients with&#xD;
             well controlled hypertension only.&#xD;
&#xD;
          -  Are not able to comply with regard to the known contraindications, warnings and&#xD;
             precautions, drug-interactions and dosing recommendations of paracetamol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Louis Abitbol, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Trophos, Parc Scientifique de Luminy - Case 931, Luminy Biotech Enterprises, 13288 Marseille Cedex9 - France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dan Ziegler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>German Diabetes Center, German Diabetes Clinic, Leibniz Institute at the Heinrich-Heine University, Auf ´m Hennekamp 65, 40225 Dusseldorf, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Univerity Hospital OSIJEK, Department for Diabetes and Endocrinology, J.Huttlera 4</name>
      <address>
        <city>Osijek</city>
        <zip>31 000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Genaral Hospital &quot;Josip Bencevic&quot;, Internal Medicine Department-Unit for Diabetes, Andrije Stampara 42</name>
      <address>
        <city>Slavonski Brod</city>
        <zip>35 000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital Varazdin, Internal Medicine Department-Unit for Diabetes, Ivana Mestrovica bb</name>
      <address>
        <city>Varazdin</city>
        <zip>42 000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital &quot;Dubrava&quot;, University Department for Internal Medicine, Institut for Diabetes, Endocrinology and Metabolic diseases, Avenija Gojka Suska 6</name>
      <address>
        <city>Zagreb</city>
        <zip>10 000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes Zentrum Mergentheim - Theodor-Klotzbücher-Straße 12</name>
      <address>
        <city>Bad Mergentheim</city>
        <zip>97980</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetologische Schwerpunktpraxis - Wilhelminenstr. 22</name>
      <address>
        <city>Dinslaken-Bruch</city>
        <zip>46537</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deutsches Diabetes Center, Institut für Klinische Diabetologie, Leibniz-Zentrum an der Heinrich-Heine Universität - Auf'm Hennekamp 65</name>
      <address>
        <city>Duesseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Region Hannover GmbH - Klinikum Hannover Nordstadt - Diabetes Schwerpunktklinik -Medizinische Klinik - Haltenhoffstr. 41</name>
      <address>
        <city>Hannover</city>
        <zip>30167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg - Abteilung Innere Medizin I und klinische Chemie - Im Neuenheimer Feld 410</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pro scientia med - Osterweide 10</name>
      <address>
        <city>Lübeck</city>
        <zip>23562</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IKFE GmbH - Institut für klinische Forschung und Entwicklung - Parcusstr. 8</name>
      <address>
        <city>Mainz</city>
        <zip>55116</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes Schwerpunktpraxis - Gesundheitszentrum Potsdam GmbH - Hebbelstr. 1A</name>
      <address>
        <city>Potsdam</city>
        <zip>14467</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes Schwerpunktpraxis - Gesundheitszentrum Potsdam GmbH, Hebbelstr. 1A</name>
      <address>
        <city>Potsdam</city>
        <zip>14467</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sophien- und Hufeland-Klinikum gGmbH - Klinik für Neurologie und Klinische Neurophysiologie - Henry-van-de-Velde-Str. 2</name>
      <address>
        <city>Weimar</city>
        <zip>99425</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Daugavpils Regional Hospital - Vasarnicu street 20</name>
      <address>
        <city>Daugavpils</city>
        <zip>LV-5420</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zemgale's Diabetes Centre SIA - Zemgales boulevard 15</name>
      <address>
        <city>Jelgava</city>
        <zip>LV-3000</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Doctor's Practice in Endocrinology - Meža prospekts 9, 2nd floor, 41.kabinets</name>
      <address>
        <city>Ogre</city>
        <zip>LV-5001</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Centre &quot;Riga&quot; - Katrinas dambis 16</name>
      <address>
        <city>Riga</city>
        <zip>LV-1045</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Talsu Hospital - Rugena street 7</name>
      <address>
        <city>Talsi</city>
        <zip>LV-3201</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Specjalistyczny Ośrodek, Internistyczno-Diabetologiczny, ul Zamenhofa 10/20</name>
      <address>
        <city>Białystok</city>
        <zip>15-435</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Neurologii Klinicznej - Ul. Dwernickiego 8</name>
      <address>
        <city>Kraków</city>
        <zip>31-530</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Special-Med. Ul. Weteranów 46</name>
      <address>
        <city>Lublin</city>
        <zip>20-044</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ MEDICA, ul. Jutrzenki 4</name>
      <address>
        <city>Lublin</city>
        <zip>20-538</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Beta-Med., Plac Wolności 17</name>
      <address>
        <city>Rzeszów</city>
        <zip>35-073</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adamiec Rajmund Gabinet Lekarski, ul. Żelazna 34</name>
      <address>
        <city>Wrocław</city>
        <zip>53-428</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre of Neurology, Clinical Hospital Centre &quot;Dr Dragisa Misovic&quot;</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic for Neurology and Psychiatry, Clinical Hospital Centre &quot;Zvezdara&quot;</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Endocrinology, Clinical Centre Serbia</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology Clinic, Military Medical Academy</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology Department, Clinical Hospital Zemun</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Neurology, Clinical Centre &quot;Kragujevac&quot;</name>
      <address>
        <city>Kragujevac</city>
        <zip>34000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Croatia</country>
    <country>Germany</country>
    <country>Latvia</country>
    <country>Poland</country>
    <country>Serbia</country>
  </location_countries>
  <removed_countries>
    <country>Former Serbia and Montenegro</country>
  </removed_countries>
  <verification_date>November 2016</verification_date>
  <study_first_submitted>June 22, 2007</study_first_submitted>
  <study_first_submitted_qc>July 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2007</study_first_posted>
  <last_update_submitted>November 21, 2016</last_update_submitted>
  <last_update_submitted_qc>November 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetic Neuropathy</keyword>
  <keyword>Painful Peripheral Diabetic Neuropathy</keyword>
  <keyword>TRO19622</keyword>
  <keyword>Trophos</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
    <mesh_term>Diabetic Neuropathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

